Exclusive: Illumina Ventures Rakes in $230M Fund, Declares Independence from Parent, Mostly

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Illumina, Arch, Bezos, Gates Bet $100M on Deep Sequencing for Early Cancer Detection
Q&A With Illumina CEO Jay Flatley on Where Genomics Is Growing
Five Things to Watch at Next Week’s Big Genomics Show